82 results on '"Cufer, T."'
Search Results
2. EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
3. Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey
4. 1826P Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: A global survey
5. 400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
6. Survie globale des patients atteints de CBNPC EGFRm+ recevant la séquence de traitement afatinib suivi d’osimertinib : analyse actualisée de l’étude GioTag
7. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
8. Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
9. PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
10. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
11. Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: Updated data from the GioTag real-world study
12. P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
13. P2.09-30 PD-L1 Testing and Clinical Benefit in Patients Treated with CPI
14. Afatinib suivi d’osimertinib en vie réelle chez des patients avec CBNPC avancé EGFR muté : étude GioTag
15. Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
16. Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
17. OA03 Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
18. Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
19. P2.15-03 Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
20. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
21. Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores
22. 154P CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: Real world data
23. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
24. 150P: EGFR mutations in circulating tumor DNA (ctDNA) and tissue rebiopsy at progression on treatment with EGFR tyrosine kinase inhibitors (TKI)
25. 5P PD-L1 expression in NSCLC
26. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
27. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
28. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
29. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
30. Double Blind Randomized Phase III Study of Maintenance Pazopanib® (Pz) Versus Placebo (P) in Non Small Cell Lung Cancer (Nsclc) Patients (Pts) Non Progressive After First Line Chemotherapy [Ct] (Eortc Lung Cancer Group, 08092): Mapping
31. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
32. Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer
33. Neutropenia in Lung Cancer Patients Treated with Chemotherapy in a Routine Clinical Practice – An Institutional Experience
34. International Research
35. Anemia in Lung Cancer and Mesothelioma Patients Treated with Chemotherapy in a Routine Clinical Practice – An Institutional Experience
36. 1st International consensus guidelines for advanced breast cancer (ABC 1)
37. Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy
38. Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment
39. 107 Comparison of Adjuvant! Online prediction with 10-year follow-up results according to the uPA and PAI-1 levels in Slovenian early breast cancer patients
40. Phase II Study of the Novel Epothilone Sagopilone (ZK-EPO) in Patients with Progressive Metastatic Breast Cancer.
41. The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen Therapy.
42. Validation of Adjuvant!Online on Slovenian collective of early breast cancer patients
43. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials
44. Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.
45. P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial (EORTC 10994/BIG 00-01).
46. S‐phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer – a multivariate study of 770 patients
47. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)
48. Expression of invasive markers (uPA/PAI-1) in four different HER ER, PR subgroups of early breast cancer
49. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
50. Adjuvant chemotherapy in 2005: Standards and beyond
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.